Tasuko Honjo was a 2018 co-winner of the Nobel Prize. Kyoto University will grant his desire to establish Japan’s first research center on cancer immunotherapy. Named the “center for general research on cancer immunity,” Honjo, at 77, will be the lead. The research will consist of five or six divisions that will involve work clarifying the mechanisms of immunity, drug development for cancer treatment and ongoing clinical trial conduct. State run, the education ministry of Japan seeks government funding for center launch in 2020.
Honjo won the Novel Prize for this cancer research that led to the development of drug Opdivo.